_migrating-eap-eapx-projects-to-qea-for-ea-v16-preview-1.jpg "Migrating .EAP .EAPX Projects to .QEA for EA v16 from eap file type Video Screenshot Preview 1")
Gallery_migrating-eap-eapx-projects-to-qea-for-ea-v16-preview-3.jpg "Migrating .EAP .EAPX Projects to .QEA for EA v16 from eap file type Video Screenshot Preview 3")
Gallery_migrating-eap-eapx-projects-to-qea-for-ea-v16-preview-hqdefault.jpg "Migrating .EAP .EAPX Projects to .QEA for EA v16 from eap file type Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 4 minutes 13 seconds
👁 View: 1.1K times
Play Audio:👁 View: 1.1K times
Description:
Dunstan Thomas Consulting
Dunstan Thomas Consulting
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_latest-weight-loss-drug-faces-shortages.webp "Latest Weight-Loss Drug , Faces Shortages .<br/>The United States Food and Drug Administration <br/>(FDA) says that high demand has left the latest <br/>weight-loss drug, Zepbound, in short supply.<br/>'Newsweek' reports that the Eli Lilly product<br/>is expected to experience limited availability <br/>through Q2 of 2024 as surging demand has <br/>outpaced the manufacturer's expectations.<br/>We have experienced <br/>an unparalleled surge in <br/>demand for our type 2 <br/>diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.<br/>We recognize this situation may <br/>cause a disruption in peoples' <br/>treatment regimens and are <br/>working with purpose and <br/>urgency to help meet <br/>the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.<br/>The FDA said that Novo Nordisk's weight-loss <br/>drug, Wegovy, is also experiencing a <br/>widespread supply shortage with no end <br/>in sight for the drug's limited availability.<br/>By the year 2030, 'Newsweek' reports <br/>that the weight-loss drug market is <br/>expected to grow to about $100 billion.<br/>We expect our investments <br/>in manufacturing and supply <br/>capacity to progressively increase <br/>production of our medicines <br/>throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.<br/>Over the past year, manufacturer Eli Lilly <br/>has already seen share prices rise over 102%.<br/>The company has announced plans <br/>to expand operations to meet increased <br/>demand for its incretin products which are <br/>used in the firm's diabetes treatments. .<br/>Incretin mimics gut hormones <br/>that regulate blood sugar <br/>while also suppressing appetite")
_eap-tls-and-peap-what-they-are-part-1.webp "cciewireless")
_what-is-type-3-diabetes.webp "While most of us are familiar with type 1 and type 2 diabetes, you may not have come across the term ‘type 3 diabetes’ before.")
_eap-extensible-authentication-protocol.webp "NetworkLobbyEddy")
_certificate-formats-sy0-601-comptia-security-3-9.webp "Professor Messer")
_latest-weight-loss-drug-faces-shortages.jpg)
_eap-tls-and-peap-what-they-are-part-1.jpg)
_what-is-type-3-diabetes.jpg)
_eap-extensible-authentication-protocol.jpg)
_certificate-formats-sy0-601-comptia-security-3-9.jpg)
![[+]](/images/menu.gif){kind=small}